Related Experiment Videos
Genes coding for tumor antigens recognized by human cytolytic T lymphocytes
P G Coulie1, P Weynants, F Lehmann
1Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|August 1, 1993
Summary
Researchers identified tumor rejection antigens, MAGE-1 and tyrosinase, recognized by cytolytic T lymphocytes (CTLs). This discovery advances specific cancer immunotherapy by targeting these melanoma antigens.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cytolytic T lymphocytes (CTLs) play a crucial role in recognizing and eliminating tumor cells.
- Identifying tumor-specific antigens is essential for developing effective cancer immunotherapies.
Purpose of the Study:
- To define the antigens recognized by CTLs on autologous tumors.
- To isolate genes encoding tumor rejection antigens for potential therapeutic applications.
Main Methods:
- Derived tumor-specific CTL clones from autologous mixed lymphocyte tumor cell cultures.
- Isolated melanoma rejection antigen gene (MAGE-1) by transfecting tumor DNA into an antigen-loss variant.
- Identified tyrosinase gene as another melanoma antigen using different CTL clones.
Main Results:
- Isolated the MAGE-1 gene, which encodes a tumor antigen presented by HLA-A1.
- Identified the tyrosinase gene as encoding an antigen presented by HLA-A2 on melanoma.
- MAGE-1 is a novel gene expressed in tumors but silent in most normal tissues (except testis).
Conclusions:
- The identification of MAGE-1 and tyrosinase as tumor rejection antigens opens new avenues for cancer immunotherapy.
- Targeting these specific antigens offers potential for developing personalized cancer treatments.
- This research highlights the importance of understanding antigen-MHC interactions in anti-tumor immunity.